Search

Igor F Tsigelny

from San Diego, CA
Age ~74
Get Report
Also known as:
Igor F Tsyguelnyi, Igor Kouznetsova, Igor I, Igor S, James Guinta, Jim Guinta
Phone and address:
3039 Guilitoy Ave, San Diego, CA 92117
(858) 581-9073
Connected to:
James J Tsighis, 87Andrey L Tsigler, 57Robert C Tsigonis, 73Vladimir Tsigrik, 77Giorgi Tsikarishvili, 35Scott J Tsikerdanos, 41Adrienne F Tsikewa, 42Charla L TsikewaNicolas G Tsikis, 72Mariam Tsiklauri, 51

Igor Tsigelny Phones & Addresses

  • 3039 Guilitoy Ave, San Diego, CA 92117 (858) 581-9073
  • La Jolla, CA

Resumes

Resumes

Igor Tsigelny Photo 1

Co-Founder And Chief Technology Officer

Location:
3039 Guilitoy Ave, San Diego, CA 92117
Industry:
Higher Education
Work:
University of California at San Diego
Research Professor
Education:
Intitute of Physics and Mechanics, Academy of Science, Ukraine 1973 - 1978
Doctor of Philosophy (Ph.D.), Physics od Polymers
Skills:
Bioinformatics
Science
Biochemistry
Molecular Biology
Molecular Modeling
Protein Chemistry
Biotechnology
Genomics
Drug Discovery
Cell Biology
Cancer
Computational Biology
Drug Design
Structural Biology
Scientific Computing
Genetics
Neuroscience
Lifesciences
Physics
Pharmacology
Statistics
Scientific Writing
Cell Culture
Life Sciences
Diabetes
Biophysics
Dna Sequencing
Docking
Systems Biology
Computational Chemistry
Molecular Dynamics
Cancer Research
Dna
Sequence Analysis
Translational Research
High Performance Computing
Drug Development
Proteomics
Machine Learning
Igor Tsigelny Photo 2

Research Professor

Location:
San Diego, CA
Work:

Research Professor
Igor Tsigelny Photo 3

Research Professor At University Of California At San Diego

Position:
Research Professor at University of California at San Diego
Location:
Greater San Diego Area
Industry:
Higher Education
Work:
University of California at San Diego
Research Professor

Business Records

Name / Title
Company / Classification
Phones & Addresses
Igor Tsigelny
Principal
International University Line
Books-Publishing/Printing
La Jolla, CA 92038
3039 Guilitoy Ave, San Diego, CA 92117
(858) 457-0595

Publications

Us Patents

Compounds For Inhibiting Protein Aggregation, And Methods For Making And Using Them

US Patent:
20100226969, Sep 9, 2010
Filed:
Jun 13, 2008
Appl. No.:
12/602689
Inventors:
Eliezer Masliah - San Diego CA, US
Igor Tsigelny - San Diego CA, US
Wolfgang Wrasidlo - La Jolla CA, US
Edward Rockenstein - Spring Valley CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 9/127
A61K 9/14
C12N 5/02
A61K 38/08
A61K 31/5513
A61K 31/5025
A61K 31/495
A61K 31/426
A61K 31/4168
C07K 7/06
C07D 243/24
C07D 487/04
C07D 403/14
C07D 277/00
C07D 233/00
A61P 25/16
A61P 25/28
US Classification:
424450, 424489, 435375, 514 15, 514 16, 514 17, 514221, 514248, 514249, 514369, 514398, 530328, 530329, 530330, 540510, 544235, 544279, 544370, 548184, 5483325
Abstract:
The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).

Compound Suitable For The Treatment Of Synucleopathies

US Patent:
20130035342, Feb 7, 2013
Filed:
Dec 16, 2010
Appl. No.:
13/516543
Inventors:
Eliezer Masliah - San Diego CA, US
Edward M. Rockenstein - Chula Vista CA, US
Wolfgang Wrasidlo - La Jolla CA, US
Igor Flint Tsigelny - San Diego CA, US
Assignee:
NEUROPORE THERAPIES, INC. - SAN DIEGO CA
International Classification:
A61K 31/496
C07D 403/14
C07D 473/00
A61K 31/52
A61P 25/00
A61K 31/454
C07D 487/04
A61K 31/519
A61P 25/16
A61P 25/28
C07D 417/14
C07D 401/14
US Classification:
51425216, 544369, 51425402, 544366, 51425405, 544277, 546199, 514322, 544280
Abstract:
The present invention relates to a compound of formula (I): Wherein Ris a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; Ris an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl group; Ris a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; L is a single bond, an alkyl group having 1 to 6 carbon atoms, NHCO, O, S, NHCONH or NHCOO; X, Y and Z are independently 0, N, NH, S or CH; W is a single bond or an alkyl group having from 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt.

Optimizing Therapeutic Options In Personalized Medicine

US Patent:
20230073255, Mar 9, 2023
Filed:
Sep 5, 2022
Appl. No.:
17/929744
Inventors:
- San Diego CA, US
Igor Flint Tsigelny - San Diego CA, US
Amélie Clémence Boichard - San Diego CA, US
Kevin Toivo BUSH - San Diego CA, US
Timothy VIET PHAM - San Diego CA, US
Stephane RICHARD - San Diego CA, US
Assignee:
CureMatch, Inc. - San Diego CA
International Classification:
C12Q 1/6883
G06F 15/173
G16H 10/60
G16H 20/10
C12Q 1/68
G06Q 10/10
G16H 50/50
G16H 20/60
Abstract:
In an aspect, a method includes obtaining patient data for a patient, the patient data including one or more molecular biomarkers specific to the patient, standardizing and curating the patient data, classifying the standardized and curated patient data including classifying the one or more molecular biomarkers by one or more of its functional effects, using the one or more functional effects for the one or more molecular biomarkers to identify a combination of available therapeutic options by targeting biomarkers with relevant functional effects based on the patient data, applying a learning method to optimize results for presentation to a user, and presenting optimized results to the user.

Method Of Prediction Of Tumor-Derived Neo-Peptide Antigenicity And/Or Immunogenicity Using Mutational Signature Patterns

US Patent:
20200362418, Nov 19, 2020
Filed:
Oct 2, 2018
Appl. No.:
16/652857
Inventors:
- SAN DIEGO CA, US
Igor Flint Tsigelny - San Diego CA, US
Amelie Clemence Boichard - ECKBOLSHEIM, FR
Timothy Viet Pham - Anaheim CA, US
Assignee:
CUREMATCH, INC. - SAN DIEGO CA
International Classification:
C12Q 1/6886
Abstract:
A method of prediction of response to immunotherapy for patients diagnosed with a proliferative, degenerative or inflammatory disease, is provided, the method comprising analysis of physicochemical properties of the set of neo-antigens produced by the injured tissue.

Optimizing Therapeutic Options In Personalized Medicine

US Patent:
20190233895, Aug 1, 2019
Filed:
Sep 8, 2017
Appl. No.:
16/331953
Inventors:
- San Diego CA, US
Igor Flint Tsigelny - San Diego CA, US
Amélie Clémence Boichard - San Diego CA, US
Kevin Toivo Bush - San Diego CA, US
Timothy Viet Pham - Anaheim CA, US
Stephane Richard - San Diego CA, US
International Classification:
C12Q 1/6883
G06F 15/173
G16H 10/60
G16H 20/10
Abstract:
In an aspect, a method includes obtaining patient data for a patient, the patient data including one or more molecular biomarkers specific to the patient, standardizing and curating the patient data, classifying the standardized and curated patient data including classifying the one or more molecular biomarkers by one or more of its functional effects, using the one or more functional effects for the one or more molecular biomarkers to identify a combination of available therapeutic options by targeting biomarkers with relevant functional effects based on the patient data, applying a learning method to optimize results for presentation to a user, and presenting optimized results to the user.

Novel Therapeutics For Brain Cancer

US Patent:
20170182049, Jun 29, 2017
Filed:
Aug 1, 2016
Appl. No.:
15/225700
Inventors:
- Oakland CA, US
Milan Makale - San Diego CA, US
Wolf Wrasidlo - La Jolla CA, US
Rajesh Mukthavaram - La Jolla CA, US
Igor Flint Tsigelny - San Diego CA, US
Valentina Lea Kouznetsova - San Diego CA, US
International Classification:
A61K 31/506
A61K 31/4545
Abstract:
Provided herein are novel compositions and methods to inhibit Olig2 activity. The Olig2 inhibitors and methods of using the same are useful, inter alia, for treating cancer. In particular the Olig2 inhibitors may be used to treat glioblastoma. Further, provided are peptide compositions capable of inhibiting Olig 2.

Novel Therapeutics For Brain Cancer

US Patent:
20150259326, Sep 17, 2015
Filed:
Nov 21, 2014
Appl. No.:
14/549900
Inventors:
- OAKLAND CA, US
Milan Makale - San Diego CA, US
Wolf Wrasidlo - La Jolla CA, US
Rajesh Mukthavaram - La Jolla CA, US
Igor Flint Tsigelny - San Diego CA, US
Valentina Lea Kouznetsova - San Diego CA, US
International Classification:
C07D 401/12
Abstract:
Provided herein are novel compositions and methods to inhibit Olig2 activity. The Olig2 inhibitors and methods of using the same are useful, inter alia, for treating cancer. In particular the Olig2 inhibitors may be used to treat glioblastoma. Further, provided are peptide compositions capable of inhibiting Olig 2.

Compound Suitable For The Treatment Of Synucleopathies

US Patent:
20140364610, Dec 11, 2014
Filed:
Aug 21, 2014
Appl. No.:
14/465773
Inventors:
- San Diego CA, US
Edward M. ROCKENSTEIN - Spring Valley CA, US
Wolfgang WRASIDLO - San Diego CA, US
Igor Flint TSIGELNY - San Diego CA, US
International Classification:
C07D 417/14
C07D 403/14
C07D 413/14
US Classification:
544369, 546201, 544366, 544373
Abstract:
The present invention relates to certain heteroaromatic compounds of Formula (Ia), or pharmaceutically acceptable salts thereof, and uses of such compounds in the treatment of synucleopathies.
Control profile
Igor F Tsigelny from San Diego, CA, age ~74 Get Report